Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: A survey of 952 patients on behalf of the acute leukemia working party of the european group for blood and marrow transplantation

Haematologica

Volumn 99, Issue 8, 2014, Pages 1380-1386

  Nagler, Arnon ^a   Labopin, Myriam ^b   Gorin, Norbert Claude ^b,c   Ferrara, Felicetto ^d   Sanz, Miguel A ^e   Wu, Depei ^f   Gomez, Antonio Torres ^g   Lapusan, Simona ^c   Irrera, Giuseppe ^h   Guimaraes, Jose E ⁱ   Sousa, Aida Botelho ^j   Carella, Angelo M ^k   Vey, Norbert ^l   Arcese, William ^m   Shimoni, Avichai ^a   Berger, Raanan ^a   Rocha, Vanderson ⁿ   Mohty, Mohamad ^b,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d CARDARELLI HOSPITAL   (Italy)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^g HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^h Azienda Ospedaliera   (Italy)

ⁱ HOSPITAL DE SÃO JOÃO   (Portugal)

^j HOSPITAL DOS CAPUCHOS   (Portugal)

^k UNIVERSITY OF GENOA   (Italy)

^l INSTITUT PAOLI CALMETTES   (France)

^m Rome Transplant Network   (Italy)

ⁿ UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CD135 ANTIGEN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IDARUBICIN; MELPHALAN; ALKYLATING AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TRANSFUSION; BONE TRANSPLANTATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CYTOGENETICS; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; GRAFT FAILURE; HEALTH SURVEY; HUMAN; INFECTION; LIVER VEIN OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; ADOLESCENT; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; EPIDEMIOLOGY; EUROPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INFORMATION PROCESSING; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; PROCEDURES; RETROSPECTIVE STUDY; SURVIVAL RATE; TRENDS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW TRANSPLANTATION; BUSULFAN; DATA COLLECTION; EUROPE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 84905197533     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.105197     Document Type: Article

References (50)

1. Buchner T, Schlenk RF, Schaich M, Dohner K, Krahl R, Krauter J, et al. Acute myeloid leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup. J Clin Oncol. 2012; 30(29): 3604-10.
2. Gorin NC. Autologous stem cell transplantation in acute myelocytic leukemia. Blood. 1998; 92(4): 1073-90.
3. Santos GW. Busulfan (Bu) and cyclophosphamide (Cy) for marrow transplantation. Bone Marrow Transplant. 1989; 4(Suppl 1): 236-9.
4. Santos GW. Allogeneic and autologous bone marrow transplantation in AML. Leukemia. 1992; 6(Suppl 2): 102-3.
5. Bleyzac N, Souillet G, Magron P, Janoly A, Martin P, Bertrand Y, et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant. 2001; 28(8): 743-51.
6. Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995; 16(1): 31-42.
7. Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, et al. Association of busulfan area under the curve with venoocclusive disease following BMT. Bone Marrow Transplant. 1996; 17(2): 225-30.
8. Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen TL, Saral R, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989; 25(1): 55-61.
9. Ljungman P, Hassan M, Bekassy AN, Ringden O, Oberg G. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant. 1997; 20(11): 909-13.
10. Bolinger AM, Zangwill AB, Slattery JT, Glidden D, DeSantes K, Heyn L, et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant. 2000; 25(9): 925-30.
11. McCune JS, Gooley T, Gibbs JP, Sanders JE, Petersdorf EW, Appelbaum FR, et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002; 30(3): 167-73.
12. Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997; 89(8): 3055-60.
13. Gibbs JP, Murray G, Risler L, Chien JY, Dev R, Slattery JT. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan. Cancer Res. 1997; 57(24): 5509-16.
14. Andersson BS, Gajewski J, Donato M, Giralt S, Gian V, Wingard J, et al. Allogeneic stem cell transplantation (BMT) for AML and MDS following i. v. busulfan and cyclophosphamide (i. v. BuCy). Bone Marrow Transplant. 2000; (Suppl 2): S35-8.
15. Vassal G, Michel G, Esperou H, Gentet JC, Valteau-Couanet D, Doz F, et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol. 2008; 61(1): 113-23.
16. Andersson BS, Kashyap A, Gian V, Wingard JR, Fernandez H, Cagnoni PJ, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant. 2002; 8(3): 145-54.
17. Gorin NC, Labopin M, Laporte JP, Douay L, Lopez M, Lesage S, et al. Importance of marrow dose on posttransplant outcome in acute leukemia: models derived from patients autografted with mafosfamide-purged marrow at a single institution. Exp Hematol. 1999; 27(12): 1822-30.
18. Gorin NC, Aegerter P, Auvert B, Meloni G, Goldstone AH, Burnett A, et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood. 1990; 75(8): 1606-14.
19. Gorin NC, Labopin M, Blaise D, Reiffers J, Meloni G, Michallet M, et al. Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remission. J Clin Oncol. 2009; 27(24): 3987-93.
20. Gorin NC, Labopin M, Frassoni F, Milpied N, Attal M, Blaise D, et al. Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8; 21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol. 2008; 26(19): 3183-8.
21. Gorin NC, Labopin M, Meloni G, Pigneux A, Esteve J, Mohamad M. Impact of FLT3 ITD/NPM1 mutation status in adult patients with acute myelocytic leukemia autografted in first remission. Haematologica. 2013; (2): e12-4.
22. Gorin NC, Labopin M, Reiffers J, Milpied N, Blaise D, Witz F, et al. Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission. Blood. 2010; 116(17): 3157-62.
23. Keating A, DaSilva G, Perez WS, Gupta V, Cutler CS, Ballen KK, et al. Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research. Haematologica. 2013; 98(2): 185-92.
24. Wang J, Ouyang J, Zhou R, Chen B, Yang Y. Autologous hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission: a meta-analysis of randomized trials. Acta Haematol. 2010; 124(2): 61-71.
25. Levi I, Grotto I, Yerushalmi R, Ben-Bassat I, Shpilberg O. Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission. Leuk Res. 2004; 28(6): 605-12.
26. Meloni G, Vignetti M, Avvisati G, Capria S, Micozzi A, Giona F, et al. BAVC regimen and autograft for acute myelogenous leukemia in second complete remission. Bone Marrow Transplant. 1996; 18(4): 693-8.
27. Fine JP, Gray RJ. A proportional hazards model for subdistribution of a competing risk. J Am Stat Assoc. 1999; 94(446): 496-509.
28. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999; 18(6): 695-706.
29. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-81.
30. Cox DR. Regression models and life tables. J R Stat Soc. 1972; 34: 187-202.
31. Czerw T, Labopin M, Gorin NC, Giebel S, Blaise D, Meloni G, et al. Long-term followup of autologous hematopoietic stem cell transplantation (AHSCT) for acute myeloid leukemia (AML): a survey of 3567 patients in CR at two years post transplantation, from the Acute Leukemia Working Party of the EBMT. Blood. 2012; 120(21): abstr 3112.
32. Sun CL, Francisco L, Kawashima T, Leisenring W, Robison LL, Baker KS, et al. Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Blood. 2010; 116(17): 3129-39; quiz 3377.
33. Burnett AK, Goldstone AH, Stevens RM, Hann IM, Rees JK, Gray RG, et al. Randomised comparison of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC-AML 10 trial. Lancet. 1998; 351(9104): 700-8.
34. Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998; 339 (23): 1649-56.
35. Harousseau JL, Cahn JY, Pignon B, Witz F, Milpied N, Delain M, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood. 1997; 90(8): 2978-86.
36. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995; 332(4): 217-23.
37. Herr AL, Labopin M, Blaise D, Milpied N, Potter M, Michallet M, et al. HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. Leukemia. 2007; 21(1): 129-35.
38. Schlenk RF, Taskesen E, van Norden Y, Krauter J, Ganser A, Bullinger L, et al. The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood. 2013; 122(9): 1576-82.
39. Holter-Chakrabarty JL, Rubinger M, Grigg A, Szer J, Selby G, Rowe JM, et al. Autologous hematopoietic cell transplantation is superior to allogeneic transplantation for acute promyelocytic leukemia in second complete remission. Blood. 2013; 122(21): 418.
40. Giebel S, Labopin M, Gorin NC, Caillot D, Leguay T, Schaap N, et al. Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: a report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Eur J Cancer. 2014; 50(2): 411-7.
41. De Lima M, Giralt S, Thall PF, de Padua Silva L, Jones RB, Komanduri K, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010; 116(23): 5420-31.
42. Bolinger AM, Zangwill AB, Slattery JT, Risler LJ, Sultan DH, Glidden DV, et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant. 2001; 28(11): 1013-8.
43. Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood. 2002; 100(4): 1201-7.
44. Hassan M. The role of busulfan in bone marrow transplantation. Med Oncol. 1999; 16(3): 166-76.
45. Lee JL, Gooley T, Bensinger W, Schiffman K, McDonald GB. Veno-occlusive disease of the liver after busulfan, melphalan and thiotepa conditioning therapy: incidence, risk factors and outcome. Biol Blood Marrow Transplant. 1999; 5(5): 306-15.
46. Lindley C, Shea T, McCune J, Shord S, Decker J, Harvey D, et al. Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy. Anticancer Drugs. 2004; 15(5): 453-9.
47. Blanes M, de la Rubia J, Lahuerta JJ, Gonzalez JD, Ribas P, Solano C, et al. Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial. Leuk Lymphoma. 2009; 50(2): 216-22.
48. Hovi L, Saxen H, Saarinen-Pihkala UM, Vettenranta K, Meri T, Richardson M. Prevention and monitoring of invasive fungal infections in pediatric patients with cancer and hematologic disorders. Pediatr Blood Cancer. 2007; 48(1): 28-34.
49. Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation. J Clin Oncol. 2013; 31(28): 3549-56.
50. Almog S, Kurnik D, Shimoni A, Loebstein R, Hassoun E, Gopher A, et al. Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination. Biol Blood Marrow Transplant. 2011; 17(1): 117-23.